advertisement
advertisement
advertisement

Illumina spinout Grail wants to build “richest database of cancer biology”

Grail, the Illumina spinout that is developing an ambitious blood test to detect cancer in the earliest stages, announced today a trial called CCGA. The goal is to perform extremely broad and deep sequencing of the genome of 10,000 people, and combine that with clinical and phenotypic data over five years. 

A company spokesperson shared that Grail’s team hopes this will be the “richest database of cancer biology and human health ever created.”CF